Products for Research Use Only

Anticancer agent 164

CAT: 0804-HY-128634Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-128634Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CML-IN-1 (compound 7) is a potent anticancer agent. CML-IN-1 displays very good induced-apoptosis effect for human chronic myeloid leukemia (CML) cell line K562. CML-IN-1 exerts its effect via a significantly reduced protein phosphorylation of PI3K/Akt signal pathway. CML-IN-1 (compound 4) also inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer[1][2].
CAS Number
2235393-30-1
UNSPSC
12352005
Target
Apoptosis; MEK; PI3K
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/anticancer-agent-164.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC=C(C(F)(F)F)C=C1)NC2=NN=C(SC3=NC=NC(NCCCN4CCOCC4)=C3)S2
Molecular Formula
C21H23F3N8O2S2
Molecular Weight
540.58
References & Citations
[1]Li W, et al. Design and synthesis of novel 1-phenyl-3- (5- (pyrimidin-4-ylthio) -1,3,4-thiadiazol- 2-yl) urea derivatives with potent anti-CML activity throughout PI3K/AKT signaling pathway. Bioorg Med Chem Lett. 2019 Jul 15;29 (14) :1831-1835.|[2]Li W, et al. A novel 4- (1,3,4-thiadiazole-2-ylthio) pyrimidine derivative inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer. Acta Pharm. 2023 Sep 14;73 (3) :489-502.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported